Advertisement
Screener

CHAMPIONS ONCOLOGY, INC. (CSBR) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum

2.6 / 5 stars · 50/98 Roast Me

CHAMPIONS ONCOLOGY, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum

CHAMPIONS ONCOLOGY, INC. (CSBR) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.50% for the 12-month period ending 2026-04-30, per its 10-K filed 2026-07-27.

Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2026-09-11

  • CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2026-01-31 was 3.84%, a 11.52% decline year-over-year.
  • CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-07-31 was 4.50%.
  • CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2025-01-31 was 4.34%.
  • CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2024-10-31 was 3.77%.
  • CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2026 was 4.50%, a 0.00% change from fiscal 2025.
  • CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2025 was 4.50%, a 0.00% change from fiscal 2024.
  • CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2024 was 4.50%, a 15.38% increase from fiscal 2023.
  • CHAMPIONS ONCOLOGY, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 3.90%, a 225.00% increase from fiscal 2022.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month as first filedShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month as first filedShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month
2026-04-304.50%
10-K · filed 2026-07-27
2026-01-313.84%
10-Q · filed 2026-03-12
4.50%
10-Q · filed 2026-03-12
2025-10-314.50%
10-Q · filed 2025-12-15
2025-07-314.50%
10-Q · filed 2026-09-11
2025-04-304.50%
10-K · filed 2026-07-27
2025-01-314.34%
10-Q · filed 2026-03-12
4.48%
10-Q · filed 2026-03-12
2024-10-313.77%
10-Q · filed 2025-12-15
4.48%
10-Q · filed 2025-12-15
2024-04-304.50%
10-K · filed 2025-07-23
2024-01-314.49%
10-Q · filed 2025-03-17
2023-10-314.49%
10-Q · filed 2024-12-16
2023-04-303.90%
10-K · filed 2024-07-19
2023-01-31370.00%
10-Q · filed 2024-03-15
3.70%
10-Q · filed 2023-03-16
2022-07-312.87%
10-Q · filed 2023-09-13
2022-04-301.20%
10-K · filed 2023-07-24
2022-01-311.20%
10-Q · filed 2023-03-16
1.20%
10-Q · filed 2023-03-16
2021-10-310.00%
10-Q · filed 2021-12-13
2021-04-300.50%
10-K · filed 2022-07-22
2021-01-310.39%
10-Q · filed 2022-03-15
2020-10-310.39%
10-Q · filed 2021-12-13
2020-04-301.80%
10-K · filed 2021-07-26
2020-01-311.80%
10-Q · filed 2021-03-15
1.80%
10-Q · filed 2021-03-15
2019-04-303.00%
10-K · filed 2020-07-28
2018-04-302.60%
10-K · filed 2019-07-29
2018-01-311.98%
10-Q · filed 2018-03-19
2017-10-311.98%
10-Q · filed 2017-12-15
2017-04-301.90%
10-K · filed 2018-07-30
2017-01-310.00%
10-Q · filed 2018-03-19
1.90%
10-Q · filed 2017-03-17
1.90%
10-Q · filed 2018-03-19
2016-10-310.00%
10-Q · filed 2017-12-15
1.48%
10-Q · filed 2016-12-14
1.48%
10-Q · filed 2017-12-15
2016-07-311.25%
10-Q · filed 2017-09-14
2016-04-301.80%
10-K · filed 2017-07-28
2016-01-311.75%
10-Q · filed 2017-03-17
1.77%
10-Q · filed 2017-03-17
2015-10-311.72%
10-Q · filed 2016-12-14
1.72%
10-Q · filed 2016-12-14
2015-07-311.77%
10-Q · filed 2016-09-14
2015-04-301.90%
10-K · filed 2016-07-29
2015-01-311.94%
10-Q · filed 2016-03-16
2014-10-311.94%
10-Q · filed 2015-12-15
1.94%
10-Q · filed 2015-12-15
2014-07-312.24%
10-Q · filed 2015-09-11
2014-04-302.40%
10-K · filed 2015-07-29
2014-01-312.10%
10-Q · filed 2015-03-17
2.40%
10-Q · filed 2015-03-17
2013-10-312.41%
10-Q · filed 2014-12-15
2.41%
10-Q · filed 2014-12-15
2013-07-311.91%
10-Q · filed 2014-09-12
2013-04-301.30%
10-K · filed 2014-07-28
2013-01-311.00%
10-Q · filed 2013-03-13
1.00%
10-Q · filed 2013-03-13
2012-10-310.90%
10-Q · filed 2013-12-13
2012-07-310.90%
10-Q · filed 2013-09-13
2012-04-302.30%
10-K · filed 2013-07-26
2012-01-311.90%
10-Q · filed 2013-03-13
2.20%
10-Q · filed 2013-03-13
2011-07-310.90%
10-Q · filed 2012-09-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
BioStem Technologies, Inc. (BSEM)United States$0.069B
Kalaris Therapeutics, Inc. (KLRS)United States$0.073B-2.19
Eloxx Pharmaceuticals, Inc. (ELOX)United States$0.065B
MiNK Therapeutics, Inc. (INKT)United States$0.063B-5.37
Vaxart, Inc. (VXRT)United States$0.080B3.84
EXOZYMES INC. (EXOZ)United States$0.058B
BioAtla, Inc. (BCAB)United States$0.058B-0.21
ImageneBio, Inc. (IMA)United States$0.056B-1.31
Inmune Bio, Inc. (INMB)United States$0.056B-2.48
Atara Biotherapeutics, Inc. (ATRA)United States$0.086B-6.48